DK2569308T3 - Nye cyclohexylaminderivater med 2-adrenerge agonist- og m3-muskarin antagonistaktiviteter - Google Patents

Nye cyclohexylaminderivater med 2-adrenerge agonist- og m3-muskarin antagonistaktiviteter Download PDF

Info

Publication number
DK2569308T3
DK2569308T3 DK11720386.9T DK11720386T DK2569308T3 DK 2569308 T3 DK2569308 T3 DK 2569308T3 DK 11720386 T DK11720386 T DK 11720386T DK 2569308 T3 DK2569308 T3 DK 2569308T3
Authority
DK
Denmark
Prior art keywords
addrenge
agonist
antagonist activities
cyclohexylamine derivatives
muscarin
Prior art date
Application number
DK11720386.9T
Other languages
Danish (da)
English (en)
Inventor
Quinones Maria Prat
Pou Silvia Fonquerna
Duran Carlos Puig
Amador Wenceslao Lumeras
Bosch Jose Aiguade
Javaloyes Juan Francisco Caturla
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Application granted granted Critical
Publication of DK2569308T3 publication Critical patent/DK2569308T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
DK11720386.9T 2010-05-13 2011-05-13 Nye cyclohexylaminderivater med 2-adrenerge agonist- og m3-muskarin antagonistaktiviteter DK2569308T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382118A EP2386555A1 (en) 2010-05-13 2010-05-13 New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
US36504510P 2010-07-16 2010-07-16
PCT/EP2011/002376 WO2011141180A1 (en) 2010-05-13 2011-05-13 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

Publications (1)

Publication Number Publication Date
DK2569308T3 true DK2569308T3 (da) 2017-02-20

Family

ID=42646365

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11720386.9T DK2569308T3 (da) 2010-05-13 2011-05-13 Nye cyclohexylaminderivater med 2-adrenerge agonist- og m3-muskarin antagonistaktiviteter

Country Status (38)

Country Link
US (1) US9643961B2 (enExample)
EP (2) EP2386555A1 (enExample)
JP (1) JP5851489B2 (enExample)
KR (1) KR101756497B1 (enExample)
CN (1) CN102892765B (enExample)
AR (1) AR081387A1 (enExample)
AU (1) AU2011252337C1 (enExample)
BR (1) BR112012026570A2 (enExample)
CA (1) CA2799099C (enExample)
CL (1) CL2012003171A1 (enExample)
CO (1) CO6592031A2 (enExample)
CR (1) CR20120574A (enExample)
CY (1) CY1118352T1 (enExample)
DK (1) DK2569308T3 (enExample)
EA (1) EA022358B1 (enExample)
EC (1) ECSP12012213A (enExample)
ES (1) ES2613355T3 (enExample)
GT (1) GT201200307A (enExample)
HR (1) HRP20170307T1 (enExample)
HU (1) HUE033244T2 (enExample)
IL (1) IL222538A (enExample)
LT (1) LT2569308T (enExample)
ME (1) ME02675B (enExample)
MX (1) MX2012012897A (enExample)
MY (1) MY171899A (enExample)
NZ (1) NZ602556A (enExample)
PE (1) PE20130215A1 (enExample)
PH (1) PH12012502237A1 (enExample)
PL (1) PL2569308T3 (enExample)
PT (1) PT2569308T (enExample)
RS (1) RS55725B1 (enExample)
SG (1) SG185007A1 (enExample)
SI (1) SI2569308T1 (enExample)
SM (2) SMT201700022T1 (enExample)
TW (1) TWI526442B (enExample)
UY (1) UY33362A (enExample)
WO (1) WO2011141180A1 (enExample)
ZA (1) ZA201207031B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2592077A1 (en) * 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) * 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
HK1210587A1 (en) 2012-11-30 2016-04-29 Harmonic Pharma Natural compounds for use in the treatment of beta-2 adrenergic receptor related diseases
MX2015007279A (es) 2012-12-18 2015-08-12 Almirall Sa Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenergicos y como antagonistas muscarinicos m3.
TWI643853B (zh) * 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201440768A (zh) * 2013-02-27 2014-11-01 Almirall Sa 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
CN105814034A (zh) * 2013-12-05 2016-07-27 奇斯药制品公司 用于治疗呼吸病的二苯甲基衍生物
KR20160086351A (ko) * 2013-12-05 2016-07-19 키에시 파르마슈티시 엣스. 피. 에이. 호흡기 질환의 치료를 위한 헤테로아릴 유도체
WO2015171753A1 (en) * 2014-05-06 2015-11-12 Visco Anthony G Methods of treating or preventing preterm labor
CN106537128B (zh) 2014-06-09 2021-06-18 生物统计股份有限公司 用于测量分析物的低成本测试条和方法
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) * 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AU2017300528C1 (en) 2016-07-19 2022-10-20 Biometry Inc. Methods of and systems for measuring analytes using batch calibratable test strips
WO2020244452A1 (zh) * 2019-06-06 2020-12-10 中国医药研究开发中心有限公司 具有β 2受体激动及M受体拮抗活性的杂环衍生物及其医药用途
US20240208951A1 (en) * 2021-02-12 2024-06-27 Gbr Laboratories Private Limited A process for preparing navafenterol and intermediates thereof
WO2025245591A1 (en) * 2024-05-31 2025-12-04 Aché Laboratórios Farmacêuticos S.A. Compounds, process for obtaining the compounds, intermediate compounds, reagent compounds, pharmaceutical compositions, pharmaceutical combinations, medicaments, uses and methods of treatment

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
IT1212742B (it) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
ATE25966T1 (de) 1983-09-26 1987-04-15 Magis Farmaceutici Aminocyclohexanol-derivate mit expektoranter wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
EP0416925A3 (en) 1989-09-07 1991-09-25 Glaxo Group Limited Use of 4-hydroxy-alpha 1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol or its salts in the treatment of allergy and inflammation
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
WO1992004928A2 (en) 1990-09-26 1992-04-02 Pharbita B.V. Inhaler devices provided with a reservoir for several doses of medium for inhaling, transporting device, whirl chamber
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
AU683036B2 (en) 1992-12-18 1997-10-30 Merck Sharp & Dohme Corp. Inhaler for powdered medications
CZ296209B6 (cs) 1995-04-14 2006-02-15 Glaxo Wellcome Inc. Inhalátor a inhalacní systém
NZ310990A (en) 1995-06-21 2000-03-27 Asta Medica Ag Pharmaceutical powder cartridge, with an integrated metering slide, and inhaler therefor
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
WO1998009632A1 (en) 1996-09-06 1998-03-12 Merck & Co., Inc. Methods and compositions for treating preterm labor
JPH1171331A (ja) * 1997-08-27 1999-03-16 Tokyo Tanabe Co Ltd アミノシクロアルキルメタノール化合物
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
CN1237051C (zh) 1999-08-20 2006-01-18 道农业科学公司 杀真菌的杂环芳族酰胺和它们的组合物、使用方法和制备
JP3917863B2 (ja) * 2000-01-31 2007-05-23 ファイザー・プロダクツ・インク Ｐｄｅ４アイソザイムの選択的阻害薬として有用なニコチンアミドベンゾ縮合複素環誘導体
EP1302458A4 (en) * 2000-07-11 2005-10-19 Banyu Pharma Co Ltd ESTERDERIVATE
IL156558A0 (en) 2000-12-28 2004-01-04 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
US7358244B2 (en) 2003-05-28 2008-04-15 Theravance, Inc. Azabicycloalkane compounds
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2353018T3 (es) 2004-07-16 2011-02-24 Almirall, S.A. Inhalador para la administración de productos farmacéuticos en polvo, y un cartucho de polvo para uso con este inhalador.
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
KR20080036632A (ko) * 2005-08-08 2008-04-28 아젠터 디스커버리 리미티드 바이시클로[2.2.1]헵트-7-일아민 유도체 및 이들의 용도
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
EA016203B1 (ru) 2006-03-20 2012-03-30 Пфайзер Лимитед Производные амина
TW200811104A (en) 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
GB0702384D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
MX2009002209A (es) 2006-10-04 2009-03-16 Pfizer Ltd Derivados de sulfonamida.
GB0700972D0 (en) 2007-01-18 2007-02-28 Imp Innovations Ltd Treatment of inflammatory disease
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
PE20090907A1 (es) 2007-07-21 2009-08-05 Boehringer Ingelheim Int Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
WO2009017813A1 (en) 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
US8148373B2 (en) 2008-02-06 2012-04-03 Astrazeneca Ab Compounds
CN101544572B (zh) 2008-03-26 2013-03-20 连云港恒邦医药科技有限公司 一种氨溴索衍生物及其制备方法
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
TR201903556T4 (tr) 2009-04-23 2019-04-22 Theravance Respiratory Co Llc Muskarinik reseptör antagonisti ve beta 2 adrenerjik reseptör agonisti aktivitesine sahip diamid bileşikleri.
KR20120061061A (ko) 2009-04-30 2012-06-12 데이진 화-마 가부시키가이샤 4 급 암모늄염 화합물
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
KR101906630B1 (ko) 2011-06-10 2018-10-10 키에시 파르마슈티시 엣스. 피. 에이. 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
MY169479A (en) 2011-06-10 2019-04-15 Chiesi Farm Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
WO2013068875A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. 2-thiopyrimidinones
UA116622C2 (uk) 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей
SI2776038T1 (en) 2011-11-11 2018-06-29 Gilead Apollo, Llc ACC INHIBITORS AND THEIR USE
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
BR112015012746A2 (pt) 2012-12-06 2017-07-11 Chiesi Farm Spa compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
TR201808698T4 (tr) 2012-12-06 2018-07-23 Chiesi Farm Spa Muskari̇ni̇k reseptör antagoni̇st ve beta2 adrenerji̇k reseptör agoni̇st faali̇yeti̇ne sahi̇p bi̇leşenler.
MX2015007279A (es) 2012-12-18 2015-08-12 Almirall Sa Nuevos derivados carbamato de ciclohexilo y quinuclidinilo que tienen actividad como agonistas b2 adrenergicos y como antagonistas muscarinicos m3.
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201440768A (zh) 2013-02-27 2014-11-01 Almirall Sa 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物

Also Published As

Publication number Publication date
ECSP12012213A (es) 2012-11-30
SI2569308T1 (sl) 2017-02-28
PT2569308T (pt) 2017-02-24
EP2569308A1 (en) 2013-03-20
AU2011252337B2 (en) 2014-07-03
CO6592031A2 (es) 2013-01-02
ME02675B (me) 2017-06-20
HUE033244T2 (hu) 2017-11-28
AU2011252337A1 (en) 2012-12-20
EP2386555A1 (en) 2011-11-16
SMT201700022T1 (it) 2017-03-08
CA2799099C (en) 2018-03-13
EP2569308B1 (en) 2016-11-23
CL2012003171A1 (es) 2013-02-15
AU2011252337C1 (en) 2014-11-27
PE20130215A1 (es) 2013-03-08
SG185007A1 (en) 2012-12-28
KR101756497B1 (ko) 2017-07-10
UY33362A (enExample) 2011-07-29
PH12012502237A1 (en) 2013-02-04
BR112012026570A2 (pt) 2017-12-19
CN102892765B (zh) 2015-04-29
NZ602556A (en) 2013-10-25
KR20130062930A (ko) 2013-06-13
AR081387A1 (es) 2012-08-29
CR20120574A (es) 2012-11-26
TWI526442B (zh) 2016-03-21
IL222538A0 (en) 2012-12-31
JP5851489B2 (ja) 2016-02-03
ZA201207031B (en) 2013-06-26
HRP20170307T1 (hr) 2017-04-21
US9643961B2 (en) 2017-05-09
CN102892765A (zh) 2013-01-23
IL222538A (en) 2015-11-30
MX2012012897A (es) 2012-12-17
EA201201541A1 (ru) 2013-04-30
US20160264557A1 (en) 2016-09-15
RS55725B1 (sr) 2017-07-31
TW201139424A (en) 2011-11-16
PL2569308T3 (pl) 2017-05-31
GT201200307A (es) 2014-06-06
CY1118352T1 (el) 2017-06-28
ES2613355T3 (es) 2017-05-24
JP2013526494A (ja) 2013-06-24
CA2799099A1 (en) 2011-11-17
SMT201700022B (it) 2017-03-08
MY171899A (en) 2019-11-06
WO2011141180A1 (en) 2011-11-17
WO2011141180A8 (en) 2012-01-19
LT2569308T (lt) 2017-01-10
EA022358B1 (ru) 2015-12-30

Similar Documents

Publication Publication Date Title
DK2569308T3 (da) Nye cyclohexylaminderivater med 2-adrenerge agonist- og m3-muskarin antagonistaktiviteter
IL288070B (en) Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
CY2021001I2 (el) Παραγωγα ετεροκυκλικου αμιδιου χρησιμα ως μικροβιοκτονα
PT2730564T (pt) Aminas heterocíclicas e suas utilizações
SMT201600252B (it) NUOVI DERIVATI DELLA CICLOESILAMMINA AVENTI ATTIVITÀ DI β2 AGONISTA ADRENERGICO E ANTAGONISTA MUSCARINICO M3
EP2605711A4 (en) THROAT FOR VERTEBRAL FACET AND METHOD OF USE
PL2648726T3 (pl) Policykliczny antagonista lpa1 i jego zastosowania
BR112014027348A2 (pt) compostos agonistas duplos gip-glp-1 e métodos
IL232478A0 (en) New cyclohexylamine derivatives possessing beta 2 adrenergic agonist and m3 muscarinic antagonist activities
EP2549865A4 (en) MRSA AND METHOD OF USE THEREOF
CO6930362A2 (es) Compuesto heterocíclico y su uso
IL235401A0 (en) St2l antagonists and methods of use
HRP20151103T1 (xx) Supstituirani triazolopiridini i njihova uporaba kao inhibitori ttk
DK2594567T3 (da) Heterocykliske alkynylbenzenforbindelser og anvendelser deraf
BR112012017441A2 (pt) compostos e métodos
IL250606A0 (en) D2 antagonists, methods of synthesis and methods of use
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
DK3345904T3 (da) Forbindelser med muskarinreceptorantagonist- og beta2-adrenerg receptoragonist-aktivitet
FI20105572A0 (fi) Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
EP2555015A4 (en) DEVICE AND METHOD FOR MEASURING DISTANCE
BR112014009006A2 (pt) compostos heterocíclicos e métodos de uso dos mesmos
BR112013006131A2 (pt) inibidores de notum pectinacetilesterase e métodos para sua utilização
PL2758371T3 (pl) Nowe tiopochodne niosące laktamy jako silne inhibitory hdac i ich zastosowania jako leki
ES2819305T8 (es) Combinación de un conjugado de naloxol-peg y un agonista opioide